Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab with platinum-based chemotherapy and maintenance in previously untreated epithelial ovarian cancer
2015-003239-36Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Jun 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of avelumab in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (3 arms), sponsored by Pfizer. Primary endpoint: Progression-free survival. Started Jun 2016; status: terminated.
02
Drugs
avelumab
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2015-003239-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003239-36.